LL-37 · DOSSIER

LL-37

Cathelicidin · hCAP-18 · Peptide · 37 AS
LEGAL DE · NOT APPROVEDEVIDENCE · EARLY CLINICAL STUDIES3 STUDIES
FIG.01 — SIGNAL CHAIN
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES · ~4493 Da
02

Mechanism of action

What LL-37 does in the body — step by step.

01

LL-37 is the only human cathelicidin — a 37-amino-acid peptide produced by proteolytic cleavage from the precursor protein hCAP-18.

02

It acts directly antimicrobially by destabilising bacterial cell membranes (cationic charge + amphipathic helical structure).

03

In addition, LL-37 has immunomodulatory functions: it activates Toll-like receptors (TLR), promotes the chemotaxis of immune cells, stimulates angiogenesis via VEGFR-2 and accelerates wound healing.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
LL-37 is one of the best studied human antimicrobial peptides and the subject of active clinical research.
LL-37 is one of the best studied human antimicrobial peptides and the subject of active clinical research.
Phase II studies investigated topical LL-37 formulations in chronic wounds (venous ulcers) and acne.
In a Phase II trial in venous leg ulcers (Lipigen, 2014), improved wound healing and biofilm reduction were described.
Further studies address the role of LL-37 deficiency in psoriasis, atopic dermatitis and pneumonia.
Systemic use scenarios beyond wound treatment and skin conditions are not clinically established.
04

Known risks

Without human data, safety statements are limited. What is known:

01
Potentially pro-inflammatory effects at high systemic concentration
02
Ambivalent evidence on its role in carcinogenesis: both tumour-suppressing and tumour-promoting effects described
03
No safety data for systemic use outside clinical studies
04
Local skin irritation possible with topical use
05
No regulated quality standards from research-chemical sources
05

Cited studies

Chronological — links lead to the source.

2001
Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3
PubMed 11297601 →
2010
LL-37-induced human mast cell chemokine production is mediated by G protein-coupled receptors and toll-like receptors
PubMed 20212109 →
2019
Topical LL-37 (human cathelicidin antimicrobial peptide) and acne vulgaris: A randomized phase IIa study
PubMed 30802515 →
06

Frequently asked questions

What is LL-37?+

LL-37 is the only human cathelicidin — a 37-amino-acid peptide produced by proteolytic cleavage from the precursor protein hCAP-18.

What type of peptide is LL-37?+

LL-37 belongs to the Antimicrobial peptide class.

What is LL-37 used for?+

In research, LL-37 has primarily been investigated in the context of: Immunomodulation, Recovery, Skin & hair. These are research findings (evidence: early clinical studies), not proven benefits in humans and not a usage recommendation.

Is LL-37 legal in Germany?+

LL-37 is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Is LL-37 FDA-approved / legal in the US?+

No. LL-37 is not FDA-approved as a drug in the US; it is mostly sold as a research chemical and not for human consumption.

Is LL-37 legal in Canada?+

No. LL-37 is not authorized by Health Canada and not intended for human consumption.

Where can I buy LL-37?+

Peptica sells nothing and names no sources. LL-37 is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of LL-37?+

Peptica publishes no dosing. There are no approved dosing guidelines for LL-37; figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.

Is LL-37 banned in sport (WADA)?+

LL-37 is currently not on the WADA Prohibited List.

What are the known risks of LL-37?+

Documented risks include: Potentially pro-inflammatory effects at high systemic concentration; Ambivalent evidence on its role in carcinogenesis: both tumour-suppressing and tumour-promoting effects described. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is LL-37?+

The evidence is classified as “early clinical studies”. 3 studies are cited on this page.

What is the molecular weight of LL-37?+

LL-37 has a molar mass of about 4493 Da.

Which peptides are related to LL-37?+

Closely related entries: BPC-157, TB-500. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanynot approved

LL-37 is not an approved medicine in the EU. Clinical studies are ongoing within regulated trial programmes. Use outside controlled studies is not covered by any approval. Not on the WADA list. Importing it as a research chemical may, depending on the context, fall under the German Medicines Act (AMG).

Legal status varies by country and can change. This is not legal advice.

STRUCTURE & MOLECULE
H₂NLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESCOOH
37
AMINO ACIDS
~4493
MOL. WEIGHT (Da)
Short plasma half-life due to rapid enzymatic degradation; no precise published value exists
HALF-LIFE
SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01